Anvelin

Maklumat utama

  • Nama dagangan:
  • Anvelin Syrup
  • Perubatan domain:
  • Manusia
  • Jenis perubatan:
  • Ubat Allopathic

Dokumen

Penyetempatan

  • Terdapat dalam:
  • Anvelin Syrup
    Malaysia
  • Bahasa:
  • Bahasa Melayu

Maklumat lain

Status

  • Sumber:
  • NPRA - National Pharmaceutical Regulatory Agency - Bahagian Regulatori Farmasi Negara
  • Nombor kebenaran:
  • MAL19910119
  • Kemaskini terakhir:
  • 31-08-2017

Risalah Maklumat Pesakit: ciri produk - komposisi, petunjuk, kesan sampingan, dos, interaksi, tindak balas buruk, kehamilan, penyusuan

Risalah Maklumat Ubat untuk Pengguna (RiMUP)

ANVELIN SYRUP

Terbutaline sulphate (1.5mg/5ml)

Apakah yang ada pada risalah ini

Apakah kegunaan Anvelin Syrup

Bagaimana Anvelin Syrup berfungsi

Sebelum menggunakan Anvelin Syrup

Cara menggunakan Anvelin Syrup

Semasa menggunakan Anvelin Syrup

Kesan-kesan sampingan

Cara

penyimpanan

pelupusan

Anvelin Syrup

Maklumat lanjut

Pengilang dan Pemegang Pendaftaran

Produk

Tarikh kemaskini RiMUP

Apakah kegunaan Anvelin Syrup

Ia membantu melegakan pengecutan otot

pada

dinding

saluran

pernafasan

yang

berlaku secara tiba-tiba dan menyebabkan

kesukaran bernafas bagi pesakit lelah dan

keradangan

pada

tiub

bronkial

dalam

paru-paru.

Bronkial

adalah

saluran

yang

menyalurkan udara ke dalam paru-paru.

Bagaimana Anvelin Syrup berfungsi

Terbutaline

adalah

bronkodilator

mengembangkan

bronkial

mengurangkan

rintangan

dalam

saluran

udara. Ini meningkatkan aliran udara ke

dalam paru-paru.

Sebelum menggunakan Anvelin Syrup

Bila tidak boleh menggunakan

Jangan gunakan Anvelin Syrup jika anda

alah (hipersensitif) terhadap bahan-bahan

yang terkandung dalam ubat ini.

Sebelum mula menggunakan

Sila

beritahu

doktor

atau

ahli

farmasi

sebelum menggunakan Anvelin Syrup jika

anda:

hamil atau merancang untuk hamil.

sedang

menyusukan

anak

atau

merancang untuk menyusu.

mempunyai kelenjar tiroid yang terlalu

aktif.

mempunyai

tekanan

darah

tinggi,

gangguan jantung atau saluran darah,

denyutan jantung yang tidak normal.

mempunyai

paras

gula

darah

yang

tinggi.

Jika mengambil ubat-ubat lain

Sila beritahu doktor atau ahli farmasi jika

anda

sedang

atau

kebelakangan

mengambil

ubat

lain,

termasuk

sebarang

ubat tanpa preskripsi.

B-blockers

propanolol

boleh

mengurangkan kesan terbutaline.

Cara menggunakan Anvelin Syrup

Berapa banyak harus digunakan

Dewasa:

10ml-15ml, tiga kali sehari.

Kanak-kanak

0.075mg (0.25ml)/kg berat badan.

Tiga kali sehari.

Bila perlu digunakan

Ikut arahan doktor atau ahli farmasi anda.

Berapa lama perlu digunakan

Ambil

ubat

mengikut

preskripsi

doktor

atau ahli farmasi. Rujuk kepada doktor atau

ahli farmasi sebelum mengambil ubat ini

untuk tempoh masa yang lebih panjang.

Jika terlupa menggunakannya

Ambil dos yang terlepas sebaik sahaja anda

teringat.

Sekiranya

sudah

hampir

masa

untuk dos seterusnya, abaikan dos terlepas

tunggu

untuk

mengambil

seterusnya pada masa biasa. Jangan ambil

berganda

untuk

menggantikan

yang tertinggal.

Jika mengambil berlebihan (terlebih dos)

Hubungi doktor anda dengan segera atau

pergi

Jabatan

Kecemasan

hospital

terdekat, jika terambil dos berlebihan. Ini

perlu dilakukan walaupun tiada sebarang

kesan

keracunan

atau

rasa

tidak

selesa.

Anda

mungkin

memerlukan

perhatian

perubatan segera.

Simptom-simptom

terlebih

termasuk

denyutan

jantung

yang

terlalu

pantas,

pergerakan

bergetar

pengembangan

saluran darah.

Semasa menggunakan Anvelin Syrup

Perkara yang perlu dilakukan

Maklumkan

kepada

semua

doktor,

doktor

gigi

ahli

farmasi

yang

merawat

anda

bahawa

anda

sedang

menggunakan Anvelin Syrup.

Beritahu

doktor

anda

dengan

segera

jika

anda

menjadi

hamil

semasa

menggunakan ubat ini.

Sentiasa cuci tangan sebelum mengambil

ubat.

Amalkan pengambilan ubat pada waktu

yang sama setiap hari.

Minum dan telan ubat secara perlahan.

Perkara yang tidak boleh dilakukan

Jangan mula mengambil sebarang ubat

baru tanpa berbincang dengan doktor

atau ahli farmasi anda.

Jangan

berkongsi

Anvelin

Syrup

dengan

sesiapa,

walaupun

mereka

mempunyai

simptom

atau

penyakit

yang sama.

Jangan ambil ubat ini tanpa preskripsi

doktor atau ahli farmasi.

Perkara yang perlu diberi perhatian

Hati-hati bila memandu atau mengendalikan

jentera

sehingga

anda

tahu

bagaimana

Anvelin Syrup boleh menggangu keupayaan

anda

untuk

memandu atau

mengendalikan

jentera.

Kesan-kesan sampingan

Getaran ringan (biasanya pada tangan).

Sakit kepala.

Gemuruh.

Pengembangan salur darah.

Denyutan jantung yang pantas.

Dapatkan rawatan perubatan dengan segera

jika

anda

mengalami

sebarang

kesan

sampingan atau masalah alahan.

Anda

boleh

melaporkan

sebarang

kesan

sampingan atau kesan advers ubat kepada

Pusat

Pemantauan

Kesan

Advers

Ubat

Kebangsaan

melalui

Tel:

85535550,

atau

lawan

portal.bpfk.gov.my

(Consumers

Reporting)

Cara

penyimpanan

dan

pelupusan

Anvelin Syrup

Penyimpanan

Simpan di bawah 30°C.

Jauhi dari kanak-kanak.

Jangan ambil ubat ini selepas tarikh luput.

Pelupusan

Ubat-ubatan

tidak

harus

dilupuskan

melalui air buangan atau sisa isi rumah.

Sila

rujuk

kepada

ahli

farmasi

anda

mengenai

cara

yang

betul

untuk

melupuskan

ubat

yang

tidak

diperlukan

lagi. Langkah-langkah ini dapat membantu

melindungi alam sekitar.

Maklumat lanjut

Rupa dan warna produk

Sirap jernih, tidak berwarna dengan perisa

cola

Bahan-bahan kandungan

Bahan aktif

Terbutaline Sulphate

Bahan-bahan tidak aktif

Sorbitol Solution, Cola Flavor, Saccharin

Sodium, Citric Acid Anhydrous, Sodium

Benzoate, Purified Water.

Risalah Maklumat Ubat untuk Pengguna (RiMUP)

ANVELIN SYRUP

Terbutaline sulphate (1.5mg/5ml)

Nombor MAL

MAL19910119A

Pengilang

dan

Pemegang

Pendaftaran

Produk

Xepa-Soul Pattinson (Malaysia) Sdn Bhd

1-5 Cheng Industrial Estate,

75250 Melaka, Malaysia.

Tarikh kemaskini RiMUP

20 Ogos 2015

Nombor Siri

BPFK(R4/1)200815/00266

5-3-2019

Morphine Sulfate Injection BP 30 mg in 1 mL ampoule

Morphine Sulfate Injection BP 30 mg in 1 mL ampoule

Safety advisory – Section 19A product not for epidural or intrathecal use

Therapeutic Goods Administration - Australia

1-2-2019

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Published on: Thu, 31 Jan 2019 The EFSA FEEDAP Panel previously (2016) could not conclude on the safety of certain concentrated liquid l‐lysine (base), l‐lysine monohydrochloride (HCl) and l‐lysine sulfate products manufactured using different strains of Corynebacterium glutamicum. New information on the safety of these products was provided by the applicant. The recipient strain C. glutamicum KCTC 12307BP qualifies for qualified presumption of safety (QPS) approach for safety assessment, the genetic mo...

Europe - EFSA - European Food Safety Authority EFSA Journal

25-10-2018

Safety of zinc chelate of methionine sulfate for the target species

Safety of zinc chelate of methionine sulfate for the target species

Published on: Wed, 24 Oct 2018 00:00:00 +0200 Zinc chelate of methionine sulfate is intended to be used as a nutritional additive (functional group: compounds of trace elements). The additive is zinc chelated with methionine in a molar ratio 1:1. It is intended to supply zinc as a nutritional additive to all animal species/categories. In 2017, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) adopted an opinion on the safety and efficacy of zinc chelate of methionine su...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks

Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks

Health Canada seized “Surfaz-SN Triple Action Cream”—an unauthorized skin cream promoted for antifungal, antibacterial and anti-inflammatory use—because it is labelled to contain prescription drugs (betamethasone dipropionate and neomycin sulphate). The product was seized from Kaf African Caribbean Market (2642 Liruma Road, Unit 2A) in Mississauga, Ontario.

Health Canada

2-7-2018

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services is voluntarily recalling two (2) lots of Neostigmine Methylsulfate 5mL syringes to the user/hospital/clinic level. The specified product lots are being recalled because of a confirmed customer complaint that some syringe units containing Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL are incorrectly labelled as Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL. Secondary packages are properly labelled as Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL.

FDA - U.S. Food and Drug Administration

18-3-2019


Orphan designation: Amikacin sulfate (liposomal), Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis, 25/07/2006, Positive

Orphan designation: Amikacin sulfate (liposomal), Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis, 25/07/2006, Positive

Orphan designation: Amikacin sulfate (liposomal), Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis, 25/07/2006, Positive

Europe - EMA - European Medicines Agency

18-3-2019


Orphan designation: Amikacin sulfate, Treatment of nontuberculous mycobacterial lung disease, 08/04/2014, Positive

Orphan designation: Amikacin sulfate, Treatment of nontuberculous mycobacterial lung disease, 08/04/2014, Positive

Orphan designation: Amikacin sulfate, Treatment of nontuberculous mycobacterial lung disease, 08/04/2014, Positive

Europe - EMA - European Medicines Agency

28-2-2019

EU/3/19/2140 (Artemida Pharma Europe Limited)

EU/3/19/2140 (Artemida Pharma Europe Limited)

EU/3/19/2140 (Active substance: Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase) - Orphan designation - Commission Decision (2019)1732 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001793

Europe -DG Health and Food Safety

25-2-2019

EU/3/14/1259 (Insmed Netherlands B.V.)

EU/3/14/1259 (Insmed Netherlands B.V.)

EU/3/14/1259 (Active substance: Amikacin sulfate) - Transfer of orphan designation - Commission Decision (2019)1625 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003885

Europe -DG Health and Food Safety

25-2-2019

EU/3/06/387 (Insmed Netherlands B.V.)

EU/3/06/387 (Insmed Netherlands B.V.)

EU/3/06/387 (Active substance: Amikacin sulfate (liposomal)) - Transfer of orphan designation - Commission Decision (2019)1624 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003770

Europe -DG Health and Food Safety

18-2-2019

EU/3/17/1956 (TxCell S.A.)

EU/3/17/1956 (TxCell S.A.)

EU/3/17/1956 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene) - Transfer of orphan designation - Commission Decision (2019)1371 of Mon, 18 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003578

Europe -DG Health and Food Safety

4-2-2019

Reyataz (Bristol-Myers Squibb Pharma EEIG)

Reyataz (Bristol-Myers Squibb Pharma EEIG)

Reyataz (Active substance: atazanavir sulphate) - Centralised - Yearly update - Commission Decision (2019)843 of Mon, 04 Feb 2019

Europe -DG Health and Food Safety

4-2-2019

Elmiron (bene-Arzneimittel GmbH)

Elmiron (bene-Arzneimittel GmbH)

Elmiron (Active substance: pentosan polysulfate sodium) - Centralised - Yearly update - Commission Decision (2019)848 of Mon, 04 Feb 2019

Europe -DG Health and Food Safety

31-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Macrogol 3350,sodium sulfate,sodium chloride,sodium ascorbate,potassium chloride (NER1006),Ascorbic acid, decision type: , therapeutic area: , PIP number: P/0315/2018

Opinion/decision on a Paediatric investigation plan (PIP): Macrogol 3350,sodium sulfate,sodium chloride,sodium ascorbate,potassium chloride (NER1006),Ascorbic acid, decision type: , therapeutic area: , PIP number: P/0315/2018

Opinion/decision on a Paediatric investigation plan (PIP): Macrogol 3350,sodium sulfate,sodium chloride,sodium ascorbate,potassium chloride (NER1006),Ascorbic acid, decision type: , therapeutic area: , PIP number: P/0315/2018

Europe - EMA - European Medicines Agency

29-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Cresemba,Isavuconazonium (sulfate), decision type: , therapeutic area: , PIP number: P/0314/2018

Opinion/decision on a Paediatric investigation plan (PIP): Cresemba,Isavuconazonium (sulfate), decision type: , therapeutic area: , PIP number: P/0314/2018

Opinion/decision on a Paediatric investigation plan (PIP): Cresemba,Isavuconazonium (sulfate), decision type: , therapeutic area: , PIP number: P/0314/2018

Europe - EMA - European Medicines Agency

28-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Sodium thiosulfate, decision type: , therapeutic area: , PIP number: P/0312/2018

Opinion/decision on a Paediatric investigation plan (PIP): Sodium thiosulfate, decision type: , therapeutic area: , PIP number: P/0312/2018

Opinion/decision on a Paediatric investigation plan (PIP): Sodium thiosulfate, decision type: , therapeutic area: , PIP number: P/0312/2018

Europe - EMA - European Medicines Agency

28-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Amikacin (sulfate), decision type: , therapeutic area: , PIP number: P/0346/2018

Opinion/decision on a Paediatric investigation plan (PIP): Amikacin (sulfate), decision type: , therapeutic area: , PIP number: P/0346/2018

Opinion/decision on a Paediatric investigation plan (PIP): Amikacin (sulfate), decision type: , therapeutic area: , PIP number: P/0346/2018

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Europe - EMA - European Medicines Agency

12-12-2018


Magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - EMEA/H/N/PSR/S/0016

Magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - EMEA/H/N/PSR/S/0016

Magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - EMEA/H/N/PSR/S/0016

Europe - EMA - European Medicines Agency

12-12-2018


Magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate: List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0016

Magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate: List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0016

Magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate: List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0016

Europe - EMA - European Medicines Agency

11-12-2018

Ziagen (ViiV Healthcare BV)

Ziagen (ViiV Healthcare BV)

Ziagen (Active substance: abacavir sulfate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8685 of Tue, 11 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/252/T/104

Europe -DG Health and Food Safety

3-12-2018


Withdrawn application: Zydax, glucuronoxylan sulfate sodium, Date of withdrawal: 03/12/2018, Initial authorisation

Withdrawn application: Zydax, glucuronoxylan sulfate sodium, Date of withdrawal: 03/12/2018, Initial authorisation

Withdrawn application: Zydax, glucuronoxylan sulfate sodium, Date of withdrawal: 03/12/2018, Initial authorisation

Europe - EMA - European Medicines Agency

22-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type: , therapeutic area: , PIP number: P/0223/2018

Europe - EMA - European Medicines Agency

19-11-2018


Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use

Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use

Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use

Europe - EMA - European Medicines Agency

30-10-2018

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate) - Orphan designation - Commission Decision (2018)7273 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/102/18

Europe -DG Health and Food Safety

2-8-2018

EU/3/07/446 (Orchard Therapeutics Ltd)

EU/3/07/446 (Orchard Therapeutics Ltd)

EU/3/07/446 (Active substance: Autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA) - Transfer of orphan designation - Commission Decision (2018)5287 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/102/06/T/02

Europe -DG Health and Food Safety

27-6-2018

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Active substance: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) - Transfer of orphan designation - Commission Decision (2018)4094 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/15/T/02

Europe -DG Health and Food Safety

19-6-2018

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Active substance: desloratadine; pseudoephedrine sulphate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3930 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/772/T/37

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1956 (Sangamo Therapeutics UK LTD)

EU/3/17/1956 (Sangamo Therapeutics UK LTD)

EU/3/17/1956 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene) - Transfer of orphan designation - Commission Decision (2018)3811 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/168/17/T/01

Europe -DG Health and Food Safety

14-5-2018

Girolan and its associated name Apralan

Girolan and its associated name Apralan

Girolan and its associated name Apralan (Active substance: Apramycin sulfate) - Community Referrals - Art 34 - Commission Decision (2018)2989 of Mon, 14 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/122

Europe -DG Health and Food Safety

21-3-2018

EU/3/16/1714 (IQVIA RDS Ireland Limited)

EU/3/16/1714 (IQVIA RDS Ireland Limited)

EU/3/16/1714 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate) - Transfer of orphan designation - Commission Decision (2018)1823 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/119/16/T/01

Europe -DG Health and Food Safety